Meeting
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
Authors
Arpit Rao
Dan L. Duncan Comprehensive Cancer Center, Baylor College of Medicine, Houston, TX
Arpit Rao , Glenn Heller , Charles J. Ryan , David James VanderWeele , Lionel D Lewis , Alan Tan , Colleen Watt , Ronald C. Chen , Manish Kohli , Pedro C. Barata , Benjamin Adam Gartrell , Robert Grubb , Amylou C. Dueck , Yujia Wen , Michael J. Morris
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04455750
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr TPS277)
DOI
10.1200/JCO.2023.41.6_suppl.TPS277
Abstract #
TPS277
Poster Bd #
P19
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2021 Genitourinary Cancers Symposium
CASPAR (Alliance A031902): A randomized, phase III trial of enzalutamide (ENZ) with rucaparib (RUCA)/placebo (PBO) as a novel therapy in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Genitourinary Cancers Symposium
BrUOG360: A phase Ib/II study of copanlisib combined with rucaparib in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Benedito A. Carneiro
Poster
2023 ASCO Genitourinary Cancers Symposium
Time-to-next treatment (TTNT) and overall survival (OS) among homologous recombination repair (HRR) positive and HRR negative patients with metastatic castration-resistant prostate cancer (mCRPC) initiating first-line (1L) therapy.
First Author: Mehmet Asim Bilen